Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults ...
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
The FDA has accepted Moderna’s revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding ...
The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...
Vaccine specialist Moderna (NASDAQ: MRNA) stock soared 5.5% through 12:55 p.m. ET Wednesday after The Wall Street Journal reported that the U.S. Food and Drug Administration will accept (note: "accept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results